Market Overview:
The global pneumococcal vaccine market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of pneumococcal diseases, increasing demand for pneumococcal vaccines and technological advancements in the field of vaccine development. However, the high cost associated with the treatment and lack of awareness about pneumococcal diseases are some factors that may restrain the growth of this market during the forecast period. Based on type, PPSV 23 accounted for majority share in 2017 and is expected to maintain its dominance during forecast period. PCV 7/13 was second largest type segment in 2017 and is projected to grow at highest CAGR from 2018-2030 owing to its benefits over other types such as PPSV 23 & PCV 10. Based on application, child segment accounted for majority share in 2017 and is projected to maintain its dominance during forecast period due high prevalence rate across globe coupled with increasing number of initiatives taken by government agencies & non-profit organizations towards child vaccination programs globally .
Product Definition:
Pneumococcal vaccine is a vaccine that helps protect against pneumococcal disease. Pneumococcal disease is a serious infection caused by the bacterium Streptococcus pneumoniae. It can cause ear infections, pneumonia, meningitis and blood infections.
PPSV 23:
PPSV 23 is a type of protein subunit vaccine, which protects against 23 types of pneumococcal bacteria. It was developed by the Public Health Service and approved for use in children aged between 2 to 17 years in 2000. The Centers for Disease Control and Prevention (CDC) recommends that all children should receive two doses of the PPSV23 vaccine as an effective measure against diseases such as meningitis, pneumonia, bloodstream infection, ear infection and otitis media.
PCV 7/13:
Polymer-based covid 13 (PCV 7/13) is a new type of vaccine developed to protect people from pneumococcal disease. PCV 7/13 was created by replacing the outer protein of the existing pneumococcal vaccines with a polysaccharide polymer, which is similar in structure to an antibody. The result was a vaccine that protects against all four types of serotypes found in children under 5 years old, including meningococcal and pneumonia serotypes.
Application Insights:
Based on the application, the global pneumococcal vaccine market is segmented into child and adult. The child application segment dominated the overall market in terms of revenue in 2017 due to higher prevalence of diseases such as chickenpox, typhoid, cholera and measles among children. Moreover, introduction of a number of vaccines for children including PCV 13 is anticipated to boost product demand over the forecast period.
The adult application segment is expected to witness significant growth over the forecast period owing to increasing awareness about preventive healthcare measures and growing incidence rate for diseases such as tuberculosis and influenza among adults. Introduction or re-introduction of a number of vaccines for adults including PPSV 23 & 23P are likely to contribute towards industry growth during this period.
Regional Analysis:
North America dominated the global market in 2017. The rising prevalence of pneumococcal disease, increasing number of government initiatives for immunization programs, and high investment by the vaccine manufacturers in this region are some factors contributing to its largest share. In addition, growing awareness about vaccines and improving healthcare infrastructure are expected to drive growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to a rise in target population along with an increase in incidence rate of pneumococcal disease coupled with increasing investments by various organizations for development of vaccines against it. Moreover, rising demand for improved healthcare facilities and better access to medical assistance is also likely boost regional market growth during the same period.
Growth Factors:
- Increasing incidence of pneumococcal infections: The global incidence of pneumococcal infections is increasing due to the rise in the number of elderly and immunocompromised individuals. This is expected to drive the demand for pneumococcal vaccines in the coming years.
- Growing awareness about pneumococcal diseases: There is a growing awareness among people about the dangers posed by pneumococcal diseases such as pneumonia, meningitis, and sepsis. This is likely to boost demand for pneumococcal vaccines in the near future.
- Technological advancements in vaccine development: The development of new and innovative technologies for vaccine production has helped reduce costs and improve efficacy of pneumococcal vaccines. This is likely to spur growth prospects for this market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pneumococcal Vaccine Market Research Report
By Type
PPSV 23, PCV 7/13, PCV 10
By Application
Child, Adult
By Companies
Pfizer, GSK, MSD, Sanofipasteur, CDIBP, ...
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Pneumococcal Vaccine Market Report Segments:
The global Pneumococcal Vaccine market is segmented on the basis of:
Types
PPSV 23, PCV 7/13, PCV 10
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Child, Adult
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GSK
- MSD
- Sanofipasteur
- CDIBP
- ...
Highlights of The Pneumococcal Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PPSV 23
- PCV 7/13
- PCV 10
- By Application:
- Child
- Adult
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pneumococcal Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pneumococcal vaccine is a vaccine that helps protect against pneumococcal infections. These infections can cause serious health problems, including pneumonia (a lung infection), meningitis (an infection of the brain and spinal cord), and blood poisoning. Pneumococcal vaccines are available in two types: polysaccharide (poliomyelitis) vaccines and conjugate (tetanus, diphtheria, pertussis [Tdap], Haemophilus influenzae type b [Hib]) vaccines. Both types help protect against different pneumococcal strains. The Hib vaccine also helps protect against meningitis caused by Hib bacteria.
Some of the key players operating in the pneumococcal vaccine market are Pfizer, GSK, MSD, Sanofipasteur, CDIBP.
The pneumococcal vaccine market is expected to register a CAGR of 10.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pneumococcal Vaccine Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pneumococcal Vaccine Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pneumococcal Vaccine Market - Supply Chain
4.5. Global Pneumococcal Vaccine Market Forecast
4.5.1. Pneumococcal Vaccine Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pneumococcal Vaccine Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pneumococcal Vaccine Market Absolute $ Opportunity
5. Global Pneumococcal Vaccine Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pneumococcal Vaccine Market Size and Volume Forecast by Type
5.3.1. PPSV 23
5.3.2. PCV 7/13
5.3.3. PCV 10
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pneumococcal Vaccine Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pneumococcal Vaccine Market Size and Volume Forecast by Application
6.3.1. Child
6.3.2. Adult
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pneumococcal Vaccine Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pneumococcal Vaccine Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pneumococcal Vaccine Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pneumococcal Vaccine Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pneumococcal Vaccine Demand Share Forecast, 2019-2029
9. North America Pneumococcal Vaccine Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pneumococcal Vaccine Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pneumococcal Vaccine Market Size and Volume Forecast by Application
9.4.1. Child
9.4.2. Adult
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pneumococcal Vaccine Market Size and Volume Forecast by Type
9.7.1. PPSV 23
9.7.2. PCV 7/13
9.7.3. PCV 10
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pneumococcal Vaccine Demand Share Forecast, 2019-2029
10. Latin America Pneumococcal Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pneumococcal Vaccine Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pneumococcal Vaccine Market Size and Volume Forecast by Application
10.4.1. Child
10.4.2. Adult
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pneumococcal Vaccine Market Size and Volume Forecast by Type
10.7.1. PPSV 23
10.7.2. PCV 7/13
10.7.3. PCV 10
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pneumococcal Vaccine Demand Share Forecast, 2019-2029
11. Europe Pneumococcal Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pneumococcal Vaccine Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pneumococcal Vaccine Market Size and Volume Forecast by Application
11.4.1. Child
11.4.2. Adult
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pneumococcal Vaccine Market Size and Volume Forecast by Type
11.7.1. PPSV 23
11.7.2. PCV 7/13
11.7.3. PCV 10
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. MarketAttractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pneumococcal Vaccine Demand Share, 2019-2029
12. Asia Pacific Pneumococcal Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pneumococcal Vaccine Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pneumococcal Vaccine Market Size and Volume Forecast by Application
12.4.1. Child
12.4.2. Adult
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pneumococcal Vaccine Market Size and Volume Forecast by Type
12.7.1. PPSV 23
12.7.2. PCV 7/13
12.7.3. PCV 10
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pneumococcal Vaccine Demand Share, 2019-2029
13. Middle East & Africa Pneumococcal Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pneumococcal Vaccine Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pneumococcal Vaccine Market Size and Volume Forecast by Application
13.4.1. Child
13.4.2. Adult
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pneumococcal Vaccine Market Size and Volume Forecast by Type
13.7.1. PPSV 23
13.7.2. PCV 7/13
13.7.3. PCV 10
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pneumococcal Vaccine Demand Share, 2019-2029
14. Competition Landscape
14.1. Global Pneumococcal Vaccine Market: Market Share Analysis
14.2. Pneumococcal Vaccine Distributors and Customers
14.3. Pneumococcal Vaccine Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. GSK
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. MSD
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofipasteur
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. CDIBP
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. ...
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
